Navigation Links
Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potentcy Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
Date:3/19/2009

Launched at the 67th Annual American Academy of Dermatology Meeting

Cranford, NJ (PRWEB) March 19, 2009 -- Atopic dermatitis (AD) is very common in the United States. It affects nearly 15 million people (1% to 3% of adults and 10% to 20% of children).1, and accounts for 10 to 20 percent of all visits to dermatologists. The key symptom is pruritus (itching), leading to the description of AD as "the itch that rashes." Topical corticosteroids have become the cornerstone of treatment for a variety of inflammatory dermatoses, including atopic dermatitis (AD), eczema, and psoriasis.2

Triax Pharmaceuticals, the marketers of Locoid Lipocream® (hydrocortisone butyrate 0.1%) the leading mid-potency corticosteroid brand, introduces a new 4 oz. size of its recently launched Locoid® Lotion.

Launched at the American Academy of Dermatology (AAD) meeting in San Francisco, Locoid® Lotion (hydrocortisone butyrate 0.1%) contains a moisturizing vehicle to cover larger areas and hairy areas of affected skin with an elegant, non-greasy application; and is indicated to treat mild-to-moderate atopic dermatitis in patients as young as 3 months of age2. Locoid Lotion and Locoid Lipocream have been formulated with high concentration of barrier-enhancing lipids. This unique feature provides skin barrier restorative properties for a wide range of patients. Locoid Lotion 0.1% may provide physicians with a formulation that is easier to apply to extensive areas of disease than creams or ointments.

Locoid Lotion (hydrocortisone butyrate 0.1% lotion) is the only class 5 corticosteroid indicated for patients with AD ages 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients2, 3. By the conclusion of one study, 89% of patients had symptoms of skin-barrier disruption eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild.

Topical Corticosteroids are widely used in the treatment of mild to moderate inflammatory skin diseases. Locoid Lotion has a wide range of benefits which include the following:

  • A new 4 oz. size for larger surface areas.
  • Easy to apply and rapidly absorbed, which in turn, makes it easy to spread over affected areas, including affected areas that are large and/or hairy. The cosmetic acceptability promotes patient compliance4.
  • Promotes hydration and enhances penetration of the active drug.
  • Non-halogenated, which allows for low risk of potential side effects.
  • Unlike the majority of topical corticosteroids, Locoid Lotion contains no irritants such as propylene glycol, lanolin, or imidurea and is formulated in a non-irritating and fragrance-free base.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid Lotion is available nationwide in a 2 fl. oz. or a 4 fl. oz. bottle.

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC
Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States. Triax sales force is comprised of dermatology sales professionals nationwide.

In addition to industry leader Locoid Lipocream and new Locoid Lotion, Triax Pharmaceuticals also markets the following products:

Tretin-X® (tretinoin) Kit is available in 0.025% cream, 0.05% cream, 0.1% cream, 0.01% gel, and 0.025% gel. Each kit contains Tretinoin cream or gel along with two cosmetic products included at no additional cost to the patient: T3™ Foaming Cleanser and T3 Soothing Moisturizer.

Minocin® (minocycline HCl) Pellet-filled Capsules Professional Acne Care (P.A.C.). The Minocin PAC system contains a 60 count bottle of Minocin Pellet-Filled Capsules (50 mg or 100 mg) and three skincare products (at no additional cost to the patient).

For more information on Locoid Lotion or other Triax products, please contact Peter Volk or Aleen Hosdaghian of Triax Pharmaceuticals, LLC, 908.372.0500. See www.locoidlotion.com and www.locoid.com for full prescribing information.

1 http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp#link_b
2 Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7:266-271.
3 Data on file.
4 Fowler JF Jr. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis 2005;75:125-131.

©2009 Triax Pharmaceuticals, LLC. All rights reserved. Locoid and Locoid Lipocream are registered trademarks of Astellas Pharma Europe B.V. Licensed to Triax Pharmaceuticals, LLC. LLT-050801

###

Read the full story at http://www.prweb.com/releases/2009/03/prweb2249514.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. Biostar Pharmaceuticals, Inc. Completes 8.6-Acre Land Purchase to House New Raw Materials Processing Plant
3. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
4. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
5. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
6. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
7. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
8. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
9. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
10. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
11. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potentcy Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1% 
(Date:2/13/2016)... ... February 13, 2016 , ... The National ... the leading national organization representing the growing community of recovering individuals (now over ... include Family Recovery in policies addressing addiction. , Although many of the ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy ... of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those ... the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams ...
(Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from Pixel Film Studios ... Cut Pro X. Each user can select from up to 40 effect overlays. With ... focus offset, hue, saturation, value, contrast, glow, and more all within a click of ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... 2016 , ... In its newly released Infusion Therapy Standards ... be used to ensure patient safety when placing an IV catheter. A key ... use of vein visualization technology in patients with difficult venous access or after ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Clinical Affairs leaders at pharmaceutical organizations are looking ... of the world. While some companies have conducted a significant number ... activity in countries such as India and ... and India are now requiring local ... countries. --> China and ...
(Date:2/12/2016)... , Feb. 12, 2016   National Community Pharmacists ... RPh, MBA issued the following statement today in response ... by the Centers for Medicare & Medicaid Services ... NCPA, beneficiary advocates and others: patient advocacy ... are still reviewing the full CMS analysis. Our initial ...
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
Breaking Medicine Technology: